Tenecteplase

Known as: t-plasminogen activator, TNK-tPA, tPA 
A 527 amino acid glycoprotein and the modified form of the naturally occurring human plasminogen activator (tPA) with tissue plasminogen activating… (More)

Topic mentions per year

Topic mentions per year

1987-2018
0204019872018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS In… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
2010
2010
INTRODUCTION The clinical benefit of thrombolytic treatment over heparin in patients with pulmonary embolism without hemodynamic… (More)
  • table 2
  • table 1
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Patients with a myocardial infarction with ST-segment elevation who present to hospitals that do not have the… (More)
  • table 1
  • table 1
  • table 2
  • table 2
  • figure 1
Is this relevant?
2009
2009
BACKGROUND Tenecteplase is a modified tissue plasminogen activator with a longer half-life and higher fibrin specificity than… (More)
Is this relevant?
2005
2005
BACKGROUND AND PURPOSE Recombinant tissue-type plasminogen activator (rtPA) is the only approved treatment in acute ischemic… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may facilitate prehospital… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
BACKGROUND Bolus fibrinolytic therapy facilitates early efficient institution of reperfusion therapy. Tenecteplase is a… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
BACKGROUND Bolus thrombolytic therapy is a simplified means of administering thrombolysis that facilitates rapid time to… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Current treatment with tissue plasminogen activator (tPA) requires an intravenous infusion (1.5-3 h) because the clearance of tPA… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?